Home / Market News / $CRDF

$CRDF news and market catalysts

The 9 most recent market catalysts affecting $CRDF, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 2 high impact 3 bullish 3 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Bullish Impact 75
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib
Cardiff Oncology's onvansertib has been granted FDA Fast Track designation for the first-line treatment of KRAS- or NRAS-mutated metastatic colorectal cancer. This is a significant…
Nov 12, 2026 Corporate Catalyst Neutral Impact 75
Cardiff Oncology Reports Third Quarter 2026 Financial Results and Business Update
Cardiff Oncology's Q3 2026 filing reveals a critical juncture for the company. While the progress with onvansertib and the planned Phase 3 trial are positive developments, the $33.…
Oct 28, 2026 Corporate Catalyst Neutral Impact 75
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
Cardiff Oncology (CRDF) announced a key leadership transition with the appointment of Dr. Leila Alland as interim Chief Medical Officer, replacing Dr. Roger Sidhu. This event is si…
Oct 22, 2026 Corporate Catalyst Bullish Impact 65
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology (CRDF) announced that its drug candidate, onvansertib, received Orphan Drug Designation from the FDA for CMML. This designation is significant because it provides …
Sep 14, 2026 Corporate Catalyst Bearish Impact 85
Cardiff Oncology Announces Settlement With Nerviano Medical Sciences And Amended 2017 Onvansertib License Agreement, Resolving All Litigation; Parties To Seek Dismissal With Prejudice
The resolution of litigation with Nerviano Medical Sciences is a significant positive for Cardiff Oncology (CRDF). Legal disputes can be a major drain on resources and create uncer…
Aug 12, 2026 Corporate Catalyst Bearish Impact 65
William Blair Downgrades Cardiff Oncology to Market Perform
William Blair analyst Andy Hsieh downgraded Cardiff Oncology (CRDF) from an 'Outperform' rating to 'Market Perform.' This change in rating indicates that the analyst no longer beli…
Aug 11, 2026 Corporate Catalyst Bullish Impact 75
Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate
Cardiff Oncology (CRDF) announced its Q2 financial results, reporting a smaller loss per share than anticipated by analysts and sales that surpassed consensus estimates. This posit…
Jul 15, 2026 Corporate Catalyst Bearish Impact 85
Cardiff Oncology shares are trading lower after the company announced a $10 million offering of 8,571,429 shares of its common stock and accompanying warrants at $1.05 per share and accompanying warrant.
The headline indicates a significant dilutive event for Cardiff Oncology. Issuing new shares and warrants at a price below the current market value (implied by the stock trading lo…
Jul 15, 2026 Corporate Catalyst Neutral Impact 75
Cardiff Oncology Announces $10M Registered Direct Offering Of 8,571,429 Shares An Accompanying Warrants At $1.05 Per Share And Accompanying Warrant
This registered direct offering by Cardiff Oncology is a significant corporate catalyst. The issuance of new shares and warrants at $1.05 per share, below its recent trading price,…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.